
We’re excited to share more about Indonesia’s NHI system! It’s incredible to see how they implemented universal healthcare and overcame unique challenges.
These insights are based on a recent interview by Alec Hogg and Ali Ghufron Mukti but through the lens of health economics and outcomes research, and access to medicines.
Of course, no system is perfect, and Indonesia’s NHI journey reminds us of the importance of constant vigilance to address challenges like funding and corruption issues.
Thank you for sharing these important lessons!
Recent Posts
Accelerating Biotechnology Patient Access in Europe Through Strategic Policy Reforms
The biotechnology patient access gap in Europe remains a critical challenge despite the continent’s scientific excellence. The EU Biotech Act offers a strategic opportunity to accelerate the delivery of advanced therapies — such as radioligand, cell and gene, and RNA-based treatments — from disco...
Insulin Substitution Portugal: Implications of Novo Nordisk’s Discontinuation
INFARMED has informed healthcare professionals about the upcoming discontinuation of several Novo Nordisk insulin products in Portugal and to provide clear guidance on insulin substitution Portugal. On 30 April 2026, INFARMED issued Circular 045/CD/100.20.200 announcing that Novo Nordisk Portu...
Dementia Pharmacotherapy Guidelines: Emphasizing Non-Pharmacological Approaches in Dutch Care
Dementia Pharmacotherapy Guidelines in the Netherlands continue to emphasize a primarily non-pharmacological approach to care. The revised Dutch pharmacotherapeutic consultation document highlights the modest clinical benefits of available drug treatments and assigns cholinesterase inhibitors (do...